Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘post-Brexit’ R&D alliance

Another £5m project led by CRUK’s Beatson Institute in Glasgow – ARCCelerate – will concentrate on finding new ways to deliver personalised therapy for bowel cancers. ... In Italy, the University of Milan-Bicocca will run the £4.5m INCAR project

Latest news

More from news
Approximately 5 fully matching, plus 208 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    The development of its sickle cell therapy and beta thalassemia has been the epitome of the biotech rollercoaster, with very promising results in one sickle cell patient raising hopes, then failing ... At EHA people already had expectations in

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... This, and near-perpetual reform, continues to confound

  • No incentive for a cure No incentive for a cure

    Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83%

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

More from intelligence
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest appointments

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    Weekly industry appointments. GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... well as a pipeline of other cell and gene therapy candidates.

More from appointments
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy.

  • How do you define a biotech company?

    ReNeuron, a leading, clinical-stage stem cell business.

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    stem cell therapy and to learn his perspective on navigating the challenges that come with developing products in this complex market. ... You have this fantastic jewel that nobody really noticed but in the end it’ s a major discovery – the PD1

  • Healthcare in the Digital Age

    Exciting developments in immunotherapy and oncology, and huge strides in gene and stem-cell therapy are matched by powerhouse collaborations between academia and industry that point to a golden age for

  • Marketing strategy in complex environments

    disease. Whilst not new, this approach is becoming increasingly effective for certain therapy areas, particularly  oncology. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving the

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics